75 results about "Terbinafine" patented technology

The present invention provides a non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of an antifungal agent to a treatment site. The composition will typically include: (a) an alkyl cellulose; (b) a hydroxyalkyl cellulose; (c) a pharmaceutically acceptable polar protic solvent; (d) an antifungal agent selected from the group of naftifine, ciclopirox, terbinafine, pharmaceutically acceptable salts thereof, and combinations thereof; (e) an glycol ether; (f) an antipruritic agent selected from the group of camphor, menthol, butamben picrate, metacresol, benzyl alcohol, camphorated metacresol, juniper tar, phenol, phenolate sodium, resorcinol, camphorated metacresol, carbolic acid, and combinations,; and (g) a solubility enhancing agent, a surfactant, a wetting agent, or a combination thereof. The present invention also provides for the use of the composition composition of the present invention, in treating a fungal infection (e.g., nail fungus) in a mammal afflicted with such an infection.

Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface includes a nail plate and / or the skin.

An improved antifungal composition for topical application to the skin and nails comprises: (1) an allylamine antifungal compound; (2) an aliphatic alcohol substituted with an aromatic substituent in which the allylamine antifungal compound is soluble to a degree that a therapeutically effective concentration of the allylamine antifungal compound can be applied topically in solution; (3) a lower aliphatic alcohol in which the aromatic alcohol is soluble; and (d) water or a water-compatible solvent mixture. The allylamine antifungal compound can be terbinafine or naftifine. The aliphatic alcohol substituted with an aromatic substituent can be benzyl alcohol or phenethyl alcohol. The lower aliphatic alcohol can be ethyl alcohol or isopropyl alcohol. In an alternative, the composition can further comprise an additional antifungal compound. Another aspect of the invention is a method for treatment of a fungal infection of skin or nails comprising administering the antifungal composition of the present invention topically to the skin or nails in an amount therapeutically effective to treat the fungal infection.

The invention provides an antifungal drug composition for external use, and a preparation method of an external preparation, and application of the composition in treating superficial fungal infections, such as tinea manus and pedis, tinea corporis, tinea cruris, tinea unguium, tinea versicolor and oidiomycosis cutis. The drug composition contains terbinafine or pharmaceutical salt thereof, sertaconazole or pharmaceutical salt thereof, and any one or multiple pharmaceutically acceptable excipient. An experimental study shows that the terbinafine or pharmaceutical salt thereof and the sertaconazole or pharmaceutical salt thereof have obvious synergistic effect when the proportion thereof in the drug composition for treating the superficial fungal infections is (1: 10) to (5: 1)(w / w). The antifungal drug composition for treating the superficial fungal infections has the advantages of being good in security, excellent in curative effect, short in treatment course, high in curing rate, low in relapse rate and the like.

A process for the preparation of Terbinafine and salts thereof by reacting 1-chloro-6,6-dimethylhept-2-en-4-yne and N-methyl-N-(1-naphthylmethyl)amine in a basic aqueous medium is disclosed. Also disclosed is a process for the preparation of 1-chloro-6,6-dimethylhept-2-en-4-yne.

The present invention relates to a synthetic method for terbinafine and analogues thereof using metal catalysts, preferably Ni (II) salts and / or complexes.

The present invention is directed to a nail lacquer consisting essentially of terbinafine as an antimycotic agent, hydroxypropyl chitosan as film forming agent, water and a lower alkanol as solvents. The invention is also directed to a method for treating onychomycosis by topically administering such a nail lacquer to a patient in need of such a treatment.

The invention provides a synthetic method of terbinafine. Monomethylamine, 1-chloromethyl naphthalene and 1-chloro-6,6-dimethyl-2-heptene-4-alkyne are subjected to a one-step reaction to generate theterbinafine. Particularly, the monomethylamine is slowly added into a solvent, and then an acid-binding agent is added; the 1-chloromethyl naphthalene and the 1-chloro-6,6-dimethyl-2-heptene-4-alkyneare simultaneously slowly dropwise added, and a dropwise adding speed is controlled so as to enable both the 1-chloromethyl naphthalene and the 1-chloro-6,6-dimethyl-2-heptene-4-alkyne to be simultaneously dropwise added up; a temperature control reaction is performed for 2 to 3 hours at a temperature of 10 to 20 DEG C; chloroform is added to extract reaction liquid, vacuum concentration is carried out on an organic layer to a dry state, and ethyl acetate is added into residues to carry out crystallization to obtain the terbinafine. The synthetic method is high in yield, simple in step and convenient to operate, generates few byproducts, and is beneficial to industrial production.

The invention discloses a medicine composition for treating skin diseases. The medicine composition contains the following raw material medicines in parts by weight: 1 part of doramectin and 1-2 parts of terbinafine. The invention further provides a preparation method for the medicine composition and an application of the medicine composition in preparation for a medicine for treating skin diseases. Pharmacological experiments indicate that the medicine composition disclosed by the invention is safe and free from toxic and side effects, fast to become effective and high in effective rate, low in medication dose and low in administration frequency, as well as wide in selective dosage forms, simple in administration mode, and suitable for large-scale clinic popularization and application.

The invention discloses a preparation method of terbinafine hydrochloride, and belongs to the technical field of medicine. According to the method, a monomethylamine aqueous solution and (E)-1, 3 dichloropropene are taken as materials to react to obtain (E)-1-methylamino-3-chlorine-propylene; then (E)-1-methylamino-3-chlorine-propylene reacts with tertiary butyl acetylene to obtain (E)-N-(6, 6-dimethyl-2-heptylene-4-alkynyl) methylamine; and then the (E)-N-(6, 6-dimethyl-2-heptylene-4-alkynyl) methylamine reacts with 1-chlorine-methylnaphthalene to obtain terbinafine, and hydrochloric acid is added for salification to obtain terbinafine hydrochloride. According to the method, materials are easy to get, the cost is low, the preparation method is simple, the yield is high, and the method is suitable for industrial production.

The invention discloses a terbinafine compound preparation for treating eczema, dermatitis, body ringworm, tinea cruris, tinea manus and pedis and the preparation method; the invention mainly uses terbinafine hydrochloride and clobetasol propionate or triamcinolone acetonide acetate, which is further matched with O / W emulsion matrix for the preparation of cream. The invention is characterized by fast onset of action, short treatment course and low recurrence rate for treating skin fungal infection with local inflammatory or chronic eczema.

The invention discloses a compound terbinafine nanomedicine used for treating skin diseases. The grain size of the medicine is 1nm-10nm, and the compound terbinafine nanomedicine comprises the following components: 0.1%-10% of terbinafine, 0.1%-15% of eugenol, 0.1%-5% of erythromycin, 0.1%-10% of oil, 10%-40% of surfactant, 4%-20% of cosurfactant and the balance of distilled water, and the total percentage by weight of the components is 100%. The medicine disclosed by the invention has the advantages of small particle size, low viscosity, good liquidity, stable properties and better percutaneous permeability, and not only has a stronger curative effect on pet dermatomycosis, but also has a strong therapeutical effect on pet bacterial skin diseases and parasitic skin diseases. The compound terbinafine nanomedicine disclosed by the invention is easy to prepare, is low in energy consumption, and can be in mass production without special equipment. The compound terbinafine nanomedicine has wide application prospects in the aspect of pet skin disease treatment.

The present invention discloses the use of allylamine derivatives, such as terbinafine, in the inhibition of cancer cell growth. Also disclosed is the synergistic efficacy of allylamine derivatives in combination with other chemotherapeutically active agents, such as nocodazole, in the inhibition of cancers.

The present invention relates to topical antifungal formulations comprising one or more antifungal (e.g., terbinafine), a lipid and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.

The invention provides graphite oxide nano silver terbinafine antifungal sustained-release thermosensitive hydrogel, and a preparation method and an application of the hydrogel. The graphite oxide nano silver terbinafine antifungal sustained-release thermosensitive hydrogel takes graphite oxide as a drug sustained-release carrier, so that the drug release and action time is prolonged; at the sametime, loaded nano silver can continuously release silver ions to assist in improving an antifungal effect; due to a special sterilization mechanism of the silver ions, a drug resistance problem is notgenerated; the recurrence probability is low; similarly, poloxamer serves as an adjuvant; a drug can be in a liquid state at the room temperature; when the drug is applied to an affected site, the drug is changed into the hydrogel due to temperature rise; the administration is convenient; the contact time of the drug with the affected site can be prolonged; in addition, since the drug exists as anano ingredient, part of the drug can permeate into skin pores in a liquid form and is changed into the hydrogel due to an effect of the body temperature; and the fungicidal action time can be further prolonged.

Disclosed is a tinea resisting cream which is used for treating diseases caused by shadow position fungus infection, such as tinea corporis, tinea cruris, extremity corporis. The medicament comprises a dozen of constituents including lauryl alcohol, terbinafine, ethyl p-hydroxybenzoate, Roxithromycin, and methyl ethylene glycol.

The invention discloses a yeast strain promoter with weakened regulation intensity and application thereof. The invention specifically discloses a DNA molecule, and the DNA molecule is a recombinant promoter with reduced or weakened regulation intensity obtained by integrating a heterologous cis-acting regulatory element with a repression effect and a yeast strain inner source endogenous promoter. According to the invention, the intensity of the yeast strain promoter can be effectively reduced by integrating the marO sequence, the gene expression level is reduced from the transcriptional level, and a new tool is provided for reducing the metabolic flux of a branch way, a decomposition way or a derivative way in yeast metabolic engineering. The metabolic flux from squalene to sterol can be effectively reduced by applying the promoter weakening strategy to weakening of a yeast squalene derivation path. The yeast strain for producing squalene, provided by the invention, can realize efficient accumulation of squalene, reduce the fermentation cost and simplify the fermentation process under the condition of not adding additional enzyme inhibitor terbinafine or other effectors, with a very good industrial application prospect.

The present invention discloses a compound of an Terbinafine or the halo-Terbinafine membrane forming gel, which comprises the components of the following weight percentages comprising 0.5 percentage to 7 percentage of alkyl cellulose, 1 percentage to 10 percentage of etherifying agent, 0.5 percentage to 5 percentage of cross linking agent, 0.5 percentage to 5 percentage of accentuator, 75 percentage to 90 percentage of dissolvant0.1 percentage to 5 percentage, of Terbinafine or the halo-Terbinafine. The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is CnH2n+2-m-l(OH)m(COOH)l. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. 1 is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the Terbinafine or the halo-Terbinafine local membrane forming gel is applied for treatment of the local fungus inflammation. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of formulations of the Terbinafine or the halo-Terbinafine in the present technique, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has the properties of long maintenance time and slow releasing of the medicine.

The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and / or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.

The invention provides a pharmaceutical composition for treating leuconychia. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 1-15 parts of an active component terbinafine, 1-15 parts of bifonazole, 15-60 parts of a capsule wall material, 5-50 parts of a hydration medium and 10-80 parts of purified water. The prepared pharmaceutical composition for treating leuconychia is high in vesicle solution encapsulation efficiency, high in permeation rate, fast to act, safe and reliable, and has a market development prospect; and the problem that fungi attached to a nail plate of a leuconychia patient cannot be killed due to thick cornifin is solved.

An antifungal liquid composition for topical administration is provided that contains turpentine and at least one of peppermint oil, mineral oil, and essential oil alcohols, and one or more antifungal medications selected from ciclopirox olamine, terbinafine, tolnaftate, microconazole, itraconazole, ketoconazole, econazole, and fluconazole, and optionally one or more antifungal essential oils, and its use in the topical treatment of fungal infection, particularly of the nail.

The invention discloses a yeast promoter with weakened regulation strength and application thereof. The invention specifically discloses a DNA molecule. The DNA molecule is a recombinant promoter with a reduced or weakened regulatory strength obtained by integrating a heterologous cis-regulatory element with a repressive effect on a yeast endogenous promoter. The invention can effectively down-regulate the strength of yeast promoter by integrating the marO sequence, reduce the gene expression level from the transcription level, and provide a new tool for down-regulating the metabolic flux of branch pathway, decomposition pathway or derivative pathway in yeast metabolic engineering transformation. Applying this promoter attenuation strategy to the attenuation of the yeast squalene-derived pathway can effectively reduce the metabolic flux from squalene to sterols. The squalene-producing yeast strain provided by the present invention can realize high-efficiency accumulation of squalene without additional addition of enzyme inhibitor terbinafine or other effectors, reduce fermentation cost, simplify fermentation process, and have great advantages. Good prospects for industrial application.

The invention relates to an animal drug, in particular to a pesticide for animals, which belongs to an external used drug suitable for disinfestation for animals or curing the skin diseases for the animals. The invention adopts the solution that the pesticide includes mandarin oil, hesperetin with purity being more than and equal to 98.6 percent and terbinafine with purity being more than and equal to 99.8 percent, and the proportion among the mandarin oil, the hesperetin and the terbinafine is 100:1 to 2:0.25 to 0.9. During the manufacturing process, the hesperetin and the terbinafine are added into the mandarin oil in sequence according to the proportion, stirred at the normal temperature to be completely dissolved and uniformly mixed to obtain the finished product. The finished product is colorless or faint yellow transparent liquid, has the delicious taste of the orange, has good treatment effect to the skin disease, the fungus diseases, the acariasis and the acarid diseases of animals such as cats, dogs and the like, and has strong repelling and killing action to various mites, lice and flea.

The invention discloses liquid medicine for preventing and killing fleas, and belongs to the technical field of epidemic prevention. The liquid medicine is prepared from, by weight, 5-50 parts of rhizoma atractylodis, 10-80 parts of coptis chinensis, 1-4 parts of terbinafine, 1-4 parts of ketoconazole, 1-4 parts of abamectin, 1-4 parts of Emma rhzomorph, 1-4 parts of eprinomectin, 1-4 parts of essential oil, 50-200 parts of garlic and 200-800 parts of brown sugar. The liquid medicine is safe and convenient to use, nontoxic to human and animal, free of pollution and capable of effectively preventing and killing fleas and louse parasitizing on pet cats and dogs, and the death rate of the fleas is large.

The invention relates to an antifungal composition. The composition includes as follows: a) terbinafine or a pharmaceutically acceptable salt thereof; b) berberine or a pharmaceutically acceptable salt thereof; and c) urea and applications thereof. An application of a drug composition in preparation of drugs for treating fungal infections is also related. The drug composition includes the terbinafine or the pharmaceutically acceptable salt thereof and the berberine or the pharmaceutically acceptable salt thereof; and fungi are selected from trichophyton, fusarium, candida and combinations thereof. The composition can enhance sterilization effects, reduce the using amount of the drugs, shorten the course of treatment or avoid drug resistance.

The invention discloses a terbinafine preparation and applications of the terbinafine preparation in tobacco leaf squalene content improvement, wherein the terbinafine preparation comprises, by weight, 10-20% of terbinafine, 5-8% of tris(dodecyl alcohol polyether-4)phosphate, and the balance of ethanol. According to the present invention, the terbinafine preparation is added during the tobacco growth process, the squalene content in the tobacco leaf can be increased, and the economic value of the tobacco leaf is improved.